MiRNA-130a promotes inflammation to accelerate atherosclerosis via the regulation of proliferator-activated receptor γ (PPARγ) expression

Fengtong Liu, Yali Liu, Yuqing Du, Youshan Li
Department of Peripheral Vascular, Dongzhimen Hospital, Beijing University of Chinese Medicine; Beijing-China

ABSTRACT

Objective: In this study, we aimed to evaluate the possible function of miR-130a in atherosclerosis (AS), protection against AS, and its molecular biological mechanism.

Methods: Apoe-/- mice were fed a high-fat diet as the AS mice model. Human umbilical vein endothelial cells (HUVECs) were used as in vitro model. Serum samples or cells were used to measure the expression of inflammation. Serum samples or cells were used to determine MiRNA expression profiles using the edgeR tool from Bioconductor. Western Blot analysis was used to assess protein expressions of proliferator-activated receptor γ (PPARγ) and nuclear factor (NF)-κB.

Results: MiRNA-130a expression was up-regulated in atherosclerotic mice. In addition, over-expression of miRNA-130a promoted inflammation factors [tumor necrosis factor (TNF)α and interleukin (IL)-1β, IL-6, and IL-8] in the in vitro model of AS. However, down-regulation of miRNA-130a reduced inflammation (suppressed TNF-α, IL-1β, IL-6 and IL-8) in the in vitro model. Furthermore, over-expression of miRNA-130a could also suppress the protein expression of PPARγ and induce NF-κB protein expression in the in vitro model of AS. However, suppression of miRNA-130a induced the protein expression of PPARγ and suppressed NF-κB protein expression in the in vitro model of AS. Activation of PPARγ reduced the pro-inflammatory effects of miRNA-130a on the AS-induced in vitro model.

Conclusion: These results strongly support that miRNA-130a suppression can protect against atherosclerosis through inhibiting inflammation by regulating the PPARγ/ NF-κB expression.

Keywords: microRNA-130a, atherosclerosis, inflammation, PPAR-gamma, NF-kappaB

Introduction

Atherosclerosis (AS) can be induced by multiple factors such as hyperlipidemia, hypertension, and smoking (1). Currently, the inflammation theory based on lipid infiltration theory and injury response theory is extensively recognized to be the pathogenesis of AS (2). First proposed by the famous scholar Ross in 1976, this theory believes that AS is a process of pathological change in which lipid accumulates in the arterial wall to form a local plaque. It is mediated by inflammatory response accompanied by the genesis of oxidative stress (OS) (3). The interactions between the immune inflammatory cells (such as macrophages and dendritic cells) and multiple inflammatory factors play a key role in AS genesis and development, which can be ascribed to the characteristics of multiple targets and complexity of inflammatory action of cytokines (2).

AS is a chronic inflammatory disease induced by multiple factors in the vascular wall (4). Studies on the regulatory effect of miRNA during AS development are ongoing (4). Nonetheless, it is believed that miRNA expression in the vascular wall cells (endothelial and smooth muscle cells) as well as the infiltrated white blood cell subsets can affect disease development (5). Typically, the role of miRNA in regulating cell growth, differentiation, proliferation, and apoptosis is being gradually discovered. Moreover, abnormal miRNA expression is verified to be closely correlated with the genesis and development of multiple diseases (6). In recent years, the role of miRNA in AS has attracted increasing attention (6). Li et al. (7) have indicated that miR-130a has a role in the regulation of tumor necrosis factor (TNF)α in osteoarthritis. Yao et al. (8) have shown that the knockdown of miR-130a-3p alleviates NF-κB in spinal cord injury.

Address for Correspondence: Dr. Youshan Li, Department of Peripheral Vascular, Dongzhimen Hospital, Beijing University of Chinese Medicine; Beijing-China
Phone: +86-010-84013346 E-mail: liyoushan11@yeah.net
Accepted Date: 24.03.2021 Available Online Date: 16.08.2021
©Copyright 2021 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com DOI:10.5152/AnatolJCardiol.2021.56721
Enzyme-linked immunosorbent assay

After induction model of AS, all the mice were sacrificed by decapitation after anesthetizing them with 35 mg/kg pentobarbital sodium. Whole blood of all the mice was used to collect serum samples at 1000 g for 10 min at 4°C, and the serum samples were saved at −80°C to measure the expression of inflammation levels using enzyme-linked immunosorbent assay (ELISA) kits. TNF-α, IL-1β, IL-6 and IL-18 were measured using TNF-α (H052), IL-1β (H002), IL-6 (H007) and IL-18 (H015) ELISA kits (Nanjing Jincheng Biology Engineering Institute).

Oil Red O staining

The blood vessels were collected and fixed with 4% paraformaldehyde for one day. The aorta was embedded in paraffin and cut into 5 µM sections on the vibrator. The aorta was then stained with hematoxylin and eosin for 15 minutes and measured with a Olympus microscope (Olympus optics, Tokyo, Japan).

Reverse transcription quantitative PCR (RT-qPCR) and miRNA expression profiles

Total RNA was extracted from cells with TRIzol reagent. The cDNA was reverse transcribed by Primerscript Kit (Takara, Dalian, China), and real-time quantitative PCR was performed using 7500 real-time PCR system (Applied Biological Systems, Forster, California, USA). RT-PCR was carried out as follows: Pre-denaturation at 94°C for 10 minutes, denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for two minutes, 40 cycles. QT PCR primers: miRNA-130a, 5' - GTCAGTGCTA-AAAGGGCAT-3' and reverse, 5' - CAGTGCGTGTCGTCGGAGT-3'; U6 forward, 5' - GCCTTGCCAAGCCTAAT-3' and reverse, 5' - CGCTTCGAAATTGCTGTCA-3'. The relative gene expression was calculated by 2-ΔΔCt method (16).

RNA samples were amplified by ovation PicoSL WTA System V2 Kit (NuGEN) and sureprint G3 human Ge V2, 8x60k microarray (Agilent). cDNAs was produced using superscript II reverse transcriptase (Biotechnology). Surescan microarray scanner was used for data acquisition, and feature extraction software v. 10.7.3.1 (Agilent, USA) was used to extract the signal, which was submitted to GEO (gene expression integrated system, registration number gse80754).

Human umbilical vein endothelial cells in vitro model of atherosclerosis

Human umbilical vein endothelial cells (HUVECs) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, MA, USA) at 37°C in an atmosphere containing 5% carbon dioxide (CO₂). MiRNA-130a (supplemented with 10% FBS), anti-miRNA-30a (anti-miRNA-130a with 10% FBS), and negative mimics (negative mimics with 10% FBS) were transfected into HUVECs using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.). HUVECs were transfected with negative mimics in the negative group, with miRNA-130a mimics in the miRNA-130a group, and with anti-miRNA-130a mimics in the anti-130a group. After trans-
fection at 37°C for six hours, the medium of all the groups was subsequently replaced with DMEM containing 10% FBS for 42 hours and treated with 100 ng lipopolysaccharide (LPS) 2000 for six hours. The cell supernatant medium was collected at 2000 g for 10 minutes at 4°C, and the level of inflammation was measured by ELISA.

**Dual-luciferase reporter assay**

According to the bioinformatics results, the 3′-untranslated region (UTR) of PPARγ was cloned into pMIR-REPORT luciferase reporter plasmids (Promega Corporation, Madison, WI, USA). PPARγ plasmids were co-transfected with miR-24 mimics into HUVECs using Lipofectamine 2000. After incubation at 37°C for 48 hours, the cells were lysed using a dual luciferase reporter assay kit (Promega Corporation).

**Western blot analysis**

According to the manufacturer’s protocol, total protein was extracted by Ripa analysis (p0013b, Beyotime) and quantified by BCA Kit (p0009, Beyotime). A total of 50 g of protein was placed on 12% sodium alkylsulfate polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. The membrane was sealed in 5% skim milk for one hour at room temperature and incubated with the main antibody overnight at 4°C: PPARγ (sc-166731, 1:1000, Santa Cruz biotechnology group), NF-κB (sc-71677, 1:1000, Santa Cruz biotechnology group), and GAPDH (sc-51631, 1:5000, Santa Cruz biotechnology group). Subsequently, the membrane was washed with tris-buffered saline and Poly-sorbate 20 (TBST) and incubated with horseradish peroxidase bound goat anti-rabbit IgG at room temperature for one hour (sc-2004, 1:5000, Santa Cruz Biotechnology). Protein detection was performed by enhanced chemiluminescence (ECL, Beijing Beyotime Institute of Biotechnology, China), and imaging was performed by sodium imaging laboratory 3.0 (Bio-Rad Laboratories).

**Immunofluorescence**

The cells were washed with phosphate-buffered saline (PBS) for 15 minutes and fixed with 4% paraformaldehyde for 15 minutes. The cells were connected with PPARγ (Sc-

---

**Figure 1.** Expression of miRNA-130a in atherosclerotic mice

A, B, C and D: TNF-α, IL-1p, IL-6, and IL-18 levels

F and G: Oil Red O staining (×100, E), gene chip and qPCR for miRNA-130a expression. Sham group; AS, miRNA-130a group.

##P<0.01 comparison with sham control group.
166731, 1:100, Santa Cruz biotechnology company) and 0.25% Trionx-100 were incubated overnight in PBS at 4°C. The cells were incubated with goat anti-rabbit IgG CFL 555 (sc-362272, 1:100, Santa Cruz biotechnology company) at 37°C for two hours and stained with 4′, 6-diamidino-2-phenylindole in the dark for 15 minutes. Cells were observed using Zeiss Axioplan 2 (Carl Zeiss MicroImaging).

Statistical analysis
All data were expressed as mean ± standard deviation (n=3) using the Statistical Package for the Social Sciences version 18.0 software (SPSS Inc., Chicago, Illinois, USA). The data between the groups were compared by student’s t test or one-way analysis of variance and post-ho test. P<0.05 was considered to be statistically significant.

Results
miRNA-130a serum levels expression in atherosclerotic mice
The serum expression levels of IL-18, IL-1β, TNF-α, and IL-6 were increased in the atherosclerotic mice model compared with those in the sham group (Fig. 1a-1d). Oil Red O staining suggested that the rate of thrombus in the atherosclerotic mice was higher than that in the sham group (Fig. 1e). In addition, the heat map or qPCR demonstrated that miRNA-130a expression was upregulated in atherosclerotic mice than that in the sham group (Fig. 1e-1g).

miRNA-130a regulated inflammation in LPS-induced HUVECs in vitro model of AS
MiRNA-130a over-expression was found to increase the levels of TNF-α, IL-1β, IL-6, and IL-18 in HUVECs in LPS-induced
Figure 3. Over-expression of miRNA-130a regulates PPARγ/NF-κB in *in vitro* human umbilical vein endothelial cells

A: qPCR for miRNA-130a expression
B: gene chip
C, D, and E: 3′-UTR of PI3K is a direct target site for miRNA-130a, luciferase activity levels, and PPARγ expression

Negative, negative control group; miRNA-130a, over-expression of miRNA-130a group.

## *P*<0.01 comparison with negative group.
HUVECs in vitro model of AS compared with those in the negative group (Fig. 2a-2d). However, down-regulation of miRNA-130a suppressed the levels of IL-18, IL-1β, TNF-α, and IL-6 in LPS-induced HUVECs in vitro model of AS compared with those in the negative group (Fig. 2e-2h).

**Figure 4.** MiRNA-130a regulates PPARγ/NF-κB in *in vitro* human umbilical vein endothelial cells

A, B, and C: PPARγ and NF-κB by statistical analysis and Western blot analysis and by over-expression of miRNA-130a

D: qPCR for miRNA-130a expression

E, F, and G: PPARγ and NF-κB by statistical analysis and Western blot analysis and by down-regulation of miRNA-130a.

Negative, negative control group; miRNA-130a, over-expression of miRNA-130a group; anti-130a, down-regulation of miRNA-130a group.

**MiRNA-130a regulated PPARγ NF-κB in HUVECs in vitro**

In this study, we analyzed the mechanism of miRNA-130a in AS. Typically, miRNA-130a mimics was used to up-regulate miRNA-130a expression in LPS-induced HUVECs in vitro model of AS (Fig. 3a). The results of the heat map revealed that over-expression of miRNA-130a reduced the expression of PPARγ and induced that of NF-κB in LPS-induced HUVECs in vitro model of AS compared with those in the negative group (Fig. 3b). Moreover, miRNA-130a targeted PPARγ, and miRNA-130a over-expression could increase the luciferase reporter activity compared with that in the negative control group (Fig. 3c and 3d). Over-expression of miRNA-130a suppressed the expression of PPARγ compared with that in the negative group (Fig. 3e). Then, miRNA-130a would reduce the PPARγ activity protein expression whereas induce that of NF-κB in HUVECs LPS-induced HUVECs in vitro model of AS, comparison with that in negative group (Fig. 4a-4c). Also,
the expression of miRNA-130a in HUVECs LPS-induced HUVECs vitro model of AS was reduced by si-miRNA-130a, comparison with that in negative group (Fig. 4d). Our results suggested that down-regulation of miRNA-130a would induce the PPARγ activity protein level and suppress that of NF-κB activity protein level in LPS-induced HUVECs vitro model of AS, comparison with that in negative group (Fig. 4e-4g).

**Activation of PPARγ diminish the function of miRNA-130a in pro-inflammation effect in LPS-induced HUVECs in vitro model**

The role of PPARγ in diminishing the function of miRNA-130a in pro-inflammatory effect in LPS-induced HUVECs in vitro model was also explored. Our findings indicated that PPARγ (2 μM of GW1929) could promote the protein expression of PPARγ and suppress that of NF-κB following miRNA-130a over-expression in LPS-induced HUVECs in vitro model of AS (Fig. S1a-S1c). Besides, activation of PPARγ could reduce the effects of miRNA-130a on increasing the levels of IL-18, IL-1β, TNF-α, and IL-6 in the LPS-induced HUVECs in vitro model of AS compared with those in the miRNA-130a group (Fig. S1d-S1g).

**Inhibition of NF-κB diminishes the function of miRNA-130a in pro-inflammation effect in LPS-induced HUVECs in vitro model**

The function of NF-κB in the mechanism of miRNA-130a in pro-inflammatory effects in the LPS-induced HUVECs in vitro model of AS was also explored. Our results indicated that si-NF-κB could reduce the protein expression of NF-κB following over-expression of miRNA-130a in LPS-induced HUVECs in vitro model of AS (Fig. S2a, S2b). However, si-NF-κB could reduce the effects of miRNA-130a on increasing the levels of IL-18, IL-1β, TNF-α, and IL-6 in LPS-induced HUVECs in vitro model of AS compared with that in over-expression of miRNA-130a group (Fig. S2c-S2f). Therefore, these results showed that NF-κB participated in the pro-inflammation effects of miRNA-130a in LPS-induced HUVECs in vitro model of AS.

**Discussion**

AS is a systemic disease involving multiple cells, factors, and steps. It is induced by the action of various injury stimulations on the arterial wall, but its pathogenesis remains incompletely illustrated yet (17). miRNA is a class of non-coding small molecular single-strand RNA, which is highly conserved in evolution (about 22 base groups) and can negatively regulate gene expression at the post-transcription level. Multiple studies have verified that miRNA is closely related to AS (15). Typically, plaque formation, development, rupture, and thrombosis are regulated by miRNA (18). Classical AS process can be divided into four stages, including initiation (endothelial activation and inflammation), genesis (sub-intima lipid deposition and foam cell formation), progression (smooth muscle cell proliferation and migration, enlarged necrotic lipid nucleus in the plaque, and angiogenesis), and endpoint (unstable plaque rupture inducing acute coronary artery event) (19). This study demonstrated that miRNA-130a expression was increased in mice with AS. Jia et al. (20) have shown that miR-130a expression in patients with coronary heart disease was down-regulated.

AS is a complicated process involving inflammation, lipid, endocrine, as well as metabolic disorders (21). PPARγ is one of the current research hotspots for AS treatment, which can suppress the inflammatory response-related gene transcription (22). In addition, it can antagonize the expression of some inflammatory factors of AS to slow down plaque development. Studies show that although high PPARγ expression can be found in the human AS plaque, only a tiny quantity of PPARγ expression can be found in the normal artery. Besides, high PPARγ expression can be seen in smooth muscle cells during early AS, and its expression quantity persistently increases with disease progression (23). Increased expression can be observed in smooth muscle cells, macrophages, and foam cells, demonstrating that PPARγ plays a crucial role during AS process (23). This study showed that over-expression of miRNA-130a reduced PPARγ protein expression and stimulated NF-κB protein expression in in vitro HUVECs. Activation of PPARγ reduced the pro-inflammation effect of miRNA-130a in in vitro model of AS. Lin et al. (24) have shown that miR-130a suppressed PPARγ interaction with 3’UTR of PPARγ mRNA in non-small cell lung cancer. This indicates that PPARγ suppression by miRNA-130a is important for sensitizing systemic inflammation of AS.

Upregulation of inflammatory factor levels has long been considered to promote AS-related injury. Numerous inflammatory factors, such as TNF-α, are related to AS and other cardiovascular diseases (25). NF-κB is a key factor in the inflammatory response, which can regulate several key enzymes in LDL modification and inflammatory mediator formation in early AS. PPAR is a transcription regulatory factor that participates in lipid metabolism, inflammation, and AS. It includes three subtypes, namely PPARα, PPARβ/δ, and PPARγ (22). Of them, PPARα can suppress inflammatory response and regulate cell proliferation and migration to restrain AS (23). In addition, PPARγ ligand or agonist can restrain the activities of monocyte/macrophage transcription factors AP-1 and NF-κB. It can also reduce the inflammatory factor TNF-α to regulate the inflammatory response in AS and prevent AS formation (12). We found that the suppressed NF-κB using si-NF-κB reversed the pro-inflammation effects of miRNA-130a in AS in vitro model. Wang et al. (14) have reported that miR-130a upregulates the mTOR pathway in high-grade serous ovarian carcinoma by regulating NF-κB expression. Our results support a pivotal pro-inflammation function of miRNA-130a in the pathological development of AS by NF-κB/PPARγ.

**Study limitations**

In this study, the sample number of six mice was relatively low and is a limitation. Further studies with larger samples and mores model are warranted. However, the data from our study indicates that miRNA-130a may regulate inflammation of AS.
Conclusion

The results of our study demonstrate that miRNA-130a expression was increased in atherosclerotic mice. Over-expression of miRNA-130a increased inflammation factor levels in in vitro HUVECs through the induction of NF-κB expression by PPARγ. Therefore, miRNA-130a might be a novel molecular target for AS therapy.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Author contributions: Concept – Y.Li; Design – F.L.; Supervision – Y.D.; Critical review – Y.Li

References


Figure S1. Activation of PPARγ reduced the effect of miRNA-130a on inflammation in in vitro model.

A, B, and C: PPARγ and NF-κB by statistical analysis and Western blot analysis.

D, E, F, and G: TNF-α, IL-1β, IL-6, IL-18 levels.

Negative, negative control group; miRNA-130a, over-expression of miRNA-130a group; PPARγ, over-expression of miRNA-130a and PPARγ group.

##P<0.01 comparison with negative group, **P<0.01 comparison with over-expression of miRNA-130a group.
**Figure S2.** Inhibition of NF-κB reduced the effect of miRNA-130a on inflammation in *in vitro* model

A and B: NF-κB by statistical analysis and Western blot analysis

C, D, E, and F: TNF-α, IL-1β, IL-6, IL-18 levels

Negative, negative control group; miRNA-130a, over-expression of miRNA-130a group; anti-NF-κB, over-expression of miRNA-130a and si-NF-κB group.

## P<0.01 comparison with negative group, ** P<0.01 comparison with over-expression of miRNA-130a group.